Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT00286494

Public ClinicalTrials.gov record NCT00286494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus

Study identification

NCT ID
NCT00286494
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Takeda
Industry
Enrollment
493 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Jul 31, 2007
Completion
Jul 31, 2007
Last update posted
Feb 2, 2012

2006 – 2007

United States locations

U.S. sites
64
U.S. states
27
U.S. cities
64
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Phoenix Arizona
Not listed Anaheim California
Not listed Artesia California
Not listed Fresno California
Not listed Mission Viejo California
Not listed Northridge California
Not listed Orange California
Not listed San Diego California
Not listed Walnut Creek California
Not listed Colorado Springs Colorado
Not listed Denver Colorado
Not listed Norwalk Connecticut
Not listed Washington D.C. District of Columbia
Not listed Clearwater Florida
Not listed Cocoa Beach Florida
Not listed Hollywood Florida
Not listed Kissimmee Florida
Not listed Longwood Florida
Not listed New Port Richey Florida
Not listed Ocala Florida
Not listed Ocoee Florida
Not listed Saint Cloud Florida
Not listed Tampa Florida
Not listed Lawrenceville Georgia
Not listed Honolulu Hawaii
Not listed Idaho Falls Idaho
Not listed Chicago Illinois
Not listed Avon Indiana
Not listed Elkhart Indiana
Not listed Evansville Indiana
Not listed Lafayette Indiana
Not listed Erlanger Kentucky
Not listed Baltimore Maryland
Not listed Sudbury Massachusetts
Not listed Chesterfield Missouri
Not listed St Louis Missouri
Not listed Omaha Nebraska
Not listed Berlin New Jersey
Not listed Burlington North Carolina
Not listed Charlotte North Carolina
Not listed Hickory North Carolina
Not listed Morehead City North Carolina
Not listed Pinehurst North Carolina
Not listed Wilmington North Carolina
Not listed Winston-Salem North Carolina
Not listed Cincinnati Ohio
Not listed Dayton Ohio
Not listed Tulsa Oklahoma
Not listed Medford Oregon
Not listed Lansdale Pennsylvania
Not listed West Grove Pennsylvania
Not listed Charleston South Carolina
Not listed Columbia South Carolina
Not listed Simpsonville South Carolina
Not listed Bristol Tennessee
Not listed Cookeville Tennessee
Not listed Milan Tennessee
Not listed Corpus Christi Texas
Not listed Dallas Texas
Not listed San Antonio Texas
Not listed Temple Texas
Not listed Texarkana Texas
Not listed Burlington Vermont

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00286494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2012 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00286494 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →